Table 1. Baseline Patient Demographic and Disease Characteristics.
Characteristic | Vemurafenib (n = 371) |
---|---|
Age, mean (SD), y | 53.5 (13.8) |
Male, n (%) | 229 (62) |
ECOG PS, n (%) | |
0 | 162 (44) |
1 | 138 (37) |
2 | 59 (16) |
3 | 12 (3) |
Metastatic melanoma stage, n (%) | |
M1a | 33 (9) |
M1b | 35 (9) |
M1c | 277 (75) |
Unresectable stage III | 24 (7) |
Unknown | 2 (<1) |
Brain metastases, n (%) | 109 (29) |
Prior cancer therapy | |
Systemic therapy, n (%) | 266 (72) |
1 Therapy | 75 (20) |
2 Therapies | 64 (17) |
≥3 Therapies | 127 (34) |
No. prior systemic therapies, mean (SD) | 2.9 (2) |
Radiotherapy, n (%) | 175 (47) |